HOME >> MEDICINE >> NEWS
Novel gene therapy may lead to cure in hemophilia A patients

A discovery by Medical College of Wisconsin and BloodCenter of Wisconsin researchers in Milwaukee may be a key to a permanent genetic cure for hemophilia A patients, including a subset who do not respond to conventional blood transfusions. The study of genetically altered hemophilia mice is published in the July 2006 edition of The Journal of Clinical Investigation.

Hemophilia A affects about one in 5,000 males who lack the hereditary blood clotting protein, Factor VIII (FVIII). Traditional treatment requires infusion of synthetic FVIII two to three times a week to control bleeding episodes. However, about 30 percent of these patients develop antibodies to FVIII, selectively inactivating its clotting properties and negating its therapeutic role. Treatment for adults who have these inhibitory antibodies can cost over $1 million annually if there is a major bleeding episode.

"We developed a Trojan horse approach cloaking FVIII in a platelet so that it is undetected by the antibodies and its clotting properties are preserved until the platelet sticks to a damaged blood vessel and releases its stored protein which now includes FVIII.," explains senior author Robert R. Montgomery, M.D., senior investigator at the BloodCenter of Wisconsin and professor of pediatric hematology at the Medical College. He is also affiliated with the Children's Research Institute.

"This is truly a landmark development for hemophilia A patients," says hematologist, Joan Gill, M.D., professor of pediatric hematology at the Medical College, and director of the Comprehensive Center for Bleeding Disorders at the BloodCenter and Children's Hospital of Wisconsin. "We look forward to the day when basic research is completed and clinical trials can begin in patients."

Normally in an injury, platelets circulating in plasma - the liquid portion of the blood - stick to the site of the blood vessel wound, activating its surface and rapidly stoppi
'"/>

Contact: Toranj Marphetia
toranj@mcw.edu
414-456-4744
Medical College of Wisconsin
3-Jul-2006


Page: 1 2 3

Related medicine news :

1. Novel candidate biomarker for heart failure also strongly predicts risk of death
2. Novel treatments may help alleviate constipation, IBS in women
3. Novel catheter technique successfully patches holes in the heart
4. Novel anti-oxidant and anti-inflammatory agent shows effectiveness on key endpoints in trial
5. Novel Ames Lab composite may replace depleted uranium
6. Novel computed imaging technique uses blurry images to enhance view
7. Novel brain areas associated with the recognition of gender, ethnicity and the identity of faces
8. Novel program enhances dementia caregivers quality of life
9. Novel therapy combinations gain ground in treating hepatitis
10. Novel stem cell technology leads to better spinal cord repair
11. Novel virus entry mechanism could lead to new drugs against poxviruses

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate Institute’s Alumni ... line-up of events for its annual meeting “Coming Home 2017,” an activity-packed weekend ... Home 2017” will be held on Friday January 27 through Sunday, January 29, ...
(Date:1/21/2017)... ... January 21, 2017 , ... The Nobel Biocare™ ... Holtzclaw in media for its creos™ line of bone regenerative products. Specifically, ... in which he utilizes creos™ allo.gain™ bone graft for a variety of bone ...
(Date:1/20/2017)... ... ... Source Vitál Apothecary, a skin and body care company dedicated to creating ... a successful visit to the 2017 ECRM Diet, Vitamin & Sports Nutrition Conference in ... nutritional, sports and health industries a chance to meet in private sessions with some ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP ... people’s everyday lives, recently attended the January ECRM Trade Show in Hilton Head, ... known for its large range of supplements that keep the body functioning at ...
(Date:1/20/2017)... York, NY (PRWEB) , ... January 20, 2017 ... ... – VW+ 001 and its sugar-free alternative VW+ 002. The drinks have been ... body with optimal conditions to perform during your workout. , After a successful ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Conference Call and Webcast to Follow Vanda Pharmaceuticals ... release results for the fourth quarter of 2016 on Wednesday, February ... ... 4:30 PM ET on Wednesday, February 15, 2017, during which management ... and other corporate activities. To participate in the conference call, please ...
(Date:1/19/2017)... 19, 2017 This report on the opioid ... scenario of the global market. Large number of chronic ... chronic constipation is a major side effect of consumption ... novel targeted therapy has been prescribed to treat opioid ... targeted medicines, and growing awareness about the therapy are ...
(Date:1/19/2017)... 2017  Stealth BioTherapeutics Inc. ( Stealth ), a ... today announced new additions to its senior leadership team: ... Officer, and Daniel Geffken as interim Chief ... Carr , Pharm.D. has been promoted to Chief Clinical ... welcome Doug and Daniel to our management team, as ...
Breaking Medicine Technology:
Cached News: